Formal Therapeutic Goods Administration (“TGA”) approval of BiomeBank’s first-generation donor derived microbiome-based therapy.
The translation of research into the development of innovative and life-saving microbial therapies is set to transform in Australia through a partnership between Hudson Institute of Medical Research and BiomeBank, a clinical stage microbiome therapeutics company.
BiomeBank appoints Mr Chris Hall as Chair, effective 17 January 2022. Mr Hall brings over 30 years’ experience and impressive track record of investment management across both public and private markets within APAC. BiomeBank’s Series A funding round anticipated to close in early 2022. Formal Therapeutic Goods Association (“TGA”) approval of…
ADELAIDE, South Australia--(BUSINESS WIRE)The company behind Australia’s first facility for the manufacturing of microbial therapies has set its sights on global impact, applying to the Therapeutic Goods Administration, Australia’s regulatory authority, for approval of their world-first biologic drug product.“In addition to our existing syringe-based therapy, we are also developing capsule based-products that will allow improved patient…
Revolutionary faecal transplants are the latest new treatment option being trialled in people living with Parkinson’s to help manage their debilitating symptoms by replenishing their healthy gut bacteria.
The urgent need for human stool donations to treat chronic gut infections could soon be eased with innovative research to develop artificial super stool. The collaborative research aims to create a new generation of microbial therapies that can replace donor-derived faecal microbiota transplantation (FMT). Technology that replicates the complex community…